Top 5 Takeaways:

  1. Significantly Lower Incidence in Vaccinated Individuals: The study found that mpox incidence among unvaccinated individuals was 9.6 times higher than among those who received two doses of JYNNEOS vaccine, and 7.4 times higher than among those who received just one dose.
  2. No Difference Between Administration Routes: Preliminary evidence suggests no significant difference in protection against mpox between subcutaneous and intradermal administration of the JYNNEOS vaccine.
  3. Large Scale Study: The research analyzed mpox cases among men aged 18–49 years across 43 U.S. jurisdictions, covering a significant population and time frame.
  4. Role of Vaccination in Mpox Prevention: The findings indicate that JYNNEOS vaccination provides protection against mpox, although the exact degree and duration of this protection are still to be determined.
  5. Public Health Implications: The study supports the recommendation for vaccine-eligible individuals to complete the 2-dose vaccination series for optimal protection against mpox.

Original Article Author and Citation

Corresponding Author

Amanda B. Payne,

Suggested Citation

Payne AB, Ray LC, Cole MM, et al. Reduced Risk for Mpox After Receipt of 1 or 2 Doses of JYNNEOS Vaccine Compared with Risk Among Unvaccinated Persons — 43 U.S. Jurisdictions, July 31–October 1, 2022. MMWR Morb Mortal Wkly Rep 2022;71:1560–1564. DOI:


The study analyzed mpox cases in 43 U.S. jurisdictions among men aged 18–49, focusing on vaccine efficacy. It found a significantly lower incidence of mpox in vaccinated individuals compared to unvaccinated ones, with a larger risk reduction in those receiving two vaccine doses.


The study conducted a comprehensive analysis of mpox cases by vaccination status, utilizing data from public health jurisdictions and vaccination registries. Statistical methods, including negative binomial regression and Cox proportional hazards regression, were employed for precise effect estimation.


This research expands our understanding of mpox incidence relative to vaccination status. The findings suggest no difference in protection from mpox between subcutaneous and intradermal vaccine administration routes. Limitations include potential data misclassification and inability to control for variables like sexual behavior changes or patient characteristics.


The study concludes that JYNNEOS vaccination significantly reduces the risk of mpox, regardless of the administration route. However, further research is needed to fully understand the magnitude and duration of this protection. The findings support public health recommendations for completing the 2-dose JYNNEOS vaccine series for optimal protection against mpox.


This has been your booster shot of MMWR Info! Please check back for more MMWR, Public Health, and Programming Tutorial content daily.

Leave a Reply

Your email address will not be published. Required fields are marked *

You may use these HTML tags and attributes:

<a href="" title=""> <abbr title=""> <acronym title=""> <b> <blockquote cite=""> <cite> <code> <del datetime=""> <em> <i> <q cite=""> <s> <strike> <strong>